CN114929241A - 用sting激动剂治疗癌症的方法 - Google Patents

用sting激动剂治疗癌症的方法 Download PDF

Info

Publication number
CN114929241A
CN114929241A CN202080071755.4A CN202080071755A CN114929241A CN 114929241 A CN114929241 A CN 114929241A CN 202080071755 A CN202080071755 A CN 202080071755A CN 114929241 A CN114929241 A CN 114929241A
Authority
CN
China
Prior art keywords
compound
administered
dose
patient
immune checkpoint
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080071755.4A
Other languages
English (en)
Chinese (zh)
Inventor
陈志坚
孙立军
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunosensor Therapy Co ltd
University of Texas System
Original Assignee
Immunosensor Therapy Co ltd
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunosensor Therapy Co ltd, University of Texas System filed Critical Immunosensor Therapy Co ltd
Publication of CN114929241A publication Critical patent/CN114929241A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202080071755.4A 2019-10-14 2020-10-14 用sting激动剂治疗癌症的方法 Pending CN114929241A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962914881P 2019-10-14 2019-10-14
US62/914,881 2019-10-14
PCT/US2020/055633 WO2021076666A1 (en) 2019-10-14 2020-10-14 Methods of treating cancer with a sting agonist

Publications (1)

Publication Number Publication Date
CN114929241A true CN114929241A (zh) 2022-08-19

Family

ID=73060121

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080071755.4A Pending CN114929241A (zh) 2019-10-14 2020-10-14 用sting激动剂治疗癌症的方法

Country Status (7)

Country Link
US (1) US20230270773A1 (https=)
EP (1) EP4045059A1 (https=)
JP (1) JP2023500045A (https=)
CN (1) CN114929241A (https=)
AU (1) AU2020366354A1 (https=)
CA (1) CA3157849A1 (https=)
WO (1) WO2021076666A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022014110A (es) * 2020-05-15 2023-01-30 Immunesensor Therapeutics Inc Tratamientos combinados de agonistas de sting con inhibidores de puntos de control inmunitario.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ746112A (en) * 2016-03-18 2023-01-27 Immune Sensor Llc Cyclic di-nucleotide compounds and methods of use
AU2017378782A1 (en) * 2016-12-20 2019-07-04 Merck Sharp & Dohme Corp. Combinations of PD-1 antagonists and cyclic dinucleotide sting agonists for cancer treatment
WO2018118665A1 (en) * 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Cyclic dinucleotide sting agonists for cancer treatment

Also Published As

Publication number Publication date
WO2021076666A1 (en) 2021-04-22
EP4045059A1 (en) 2022-08-24
AU2020366354A1 (en) 2022-03-17
JP2023500045A (ja) 2023-01-04
CA3157849A1 (en) 2021-04-22
US20230270773A1 (en) 2023-08-31

Similar Documents

Publication Publication Date Title
JP6322413B2 (ja) 改善されたがん治療のための局所および全身性免疫修飾療法の組み合わせ
US20180036395A1 (en) Dosage and administration of monospecific and bispecific anti-igr-1r and anti-erbb3 antibodies
Idriss et al. Treatments on the horizon for locally advanced basal cell carcinoma
CN114929241A (zh) 用sting激动剂治疗癌症的方法
US20210380695A1 (en) Sting agonist combination treatments with immune checkpoint inhibitors
CA3089875A1 (en) Improved interferon therapy
US20240335464A1 (en) Administration of sting agonist, checkpoint inhibitors, and radiation
US20230121320A1 (en) Sting agonist combination treatments with cytokines
JP2022551672A (ja) 乳癌治療法
EP0839046B1 (en) Tnf receptor and steroid hormone dhea in a combined therapy
HK40076423A (en) Methods of treating cancer with a sting agonist
US12240904B2 (en) Use of anti-PD-1 antibody in combination with famitinib in preparation of drug for treating tumors
HK40087098A (zh) Sting激动剂与免疫检查点抑制剂的联合治疗
WO2025021587A1 (en) Combination of a mps1 inhibitor and immune checkpoint inhibitors, uses and pharmaceutical compositions thereof
Yang et al. EXTH-77. POLIO VIROTHERAPY OF MURINE BRAIN TUMORS INDUCES MICROGLIA PROLIFERATION AND INFLAMMATION THAT IS POTENTIATED BY IMMUNE CHECKPOINT BLOCKADE
HK1009403B (en) Tnf receptor and steroid hormone dhea in a combined therapy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40076423

Country of ref document: HK